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Abstract. CD44 is a ubiquitous urface molecule that 
exists as a number of isoforms, generated by alterna- 
tive splicing of 10 "variant" exons. Little is known 
about the expression and function of the variant iso- 
forms, except hat certain isoforms may play a role in 
cancer metastasis. We produced mAbs against CD44 
variant regions encoded by exons 4v, 6v, and 9v, by 
immunizing mice with a fusion protein spanning vari- 
ant exons 3v to 10v. A comprehensive analysis of hu- 
man tissues revealed that CD44 variant isoforms were 
expressed widely throughout the body, principally by 
epithelial cells. However there was differential expres- 
sion of CD44 variant exons by different epithelia. 
Most epithelia expressed exon 9v, but much fewer ex- 
pressed 6v or 4v. The regions of epithelia that 
expressed the highest levels of the variant isoforms 
were the generative cells, particularly the basal cells 
of stratified squamous epithelium, and of glandular ep- 
ithelium. CD44 variant isoforms were also expressed 
differentially by leukocytes, with CD44-9v expressed 
at very low levels and CD44-6v and 4v virtually ab- 
sent. However, CIM4-9v and CD44-6v were the main 
variants that were transiently upregulated on T cells 
after mitogenic stimulation and on myelomonocytic 
cell lines by TNFot and IFN~ treatment. Some epithe- 
lial cell lines could preferentially upregulate CIM4-6v 
upon IFN3, incubation. These results show that CD44 
variant isoforms are expressed much more widely than 
first appreciated, and that expression of the variant 
isoforms on some cell types can be modulated by par- 
ticular cytokines. 
C 
D44 is a widely expressed cell surface glycoprotein 
that serves as an adhesion molecule in cell-substrate 
and cell-cell interactions, including lymphocyte hom- 
ing, hemopoiesis, cell migration, and metastasis (for reviews 
see Haynes et al., 1991; Underhill, 1992; Gtinthert, 1993; 
Lesley et al., 1993). CD44 also has other functions that re- 
late to lymphocyte activation (Haynes et al., 1989) and the 
binding of certain cytokines to endothelium (Tanaka et al., 
1993). CD44 is a proteoglycan with an NH2-terminal re- 
gion that is structurally related to several hyaluronate bind- 
ing proteins (Underhill, 1992). CD44 is known to bind 
hyaluronate and collagen (Carter and Wayner, 1988; Aruffo 
et al., 1990; Culty et al., 1990; Miyake et al., 1990) and a 
chondroitin sulfated form of CD44 binds fibronectin (Jalka- 
nen and Jalkanen, 1992). Additional igands for CD44 may 
well exist. The numerous functions and molecular interac- 
tions of CD44 probably relate to its complex structure. In 
addition to the "standard" 85-95-kD form (CD44s), several 
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larger "variant" isoforms exist (CD44v) t that are generated 
by alternative splicing of at least 10 exons (Screaton et al., 
1992; Giinthert, 1993). PCR and Northern analyses have 
demonstrated that certain combinations ofthe variant exons 
are expressed on epithelial cells, carcinomas, and some 
hemopoietic cells (Brown et al., 1991; Dougherty et al., 
1991; Giinthert et al., 1991; Hofmann et al., 1991; Stamen- 
kovic et al., 1991; Cooper et al., 1992; He et al., 1992; 
Jackson et al., 1992; Kugelman et al., 1992; Screaton et 
al., 1992). 
Little is known about he function or regulation of CD44v 
molecules. Expression of CD44v in some tissues appears to 
relate to tumor progression, particularly the metastatic po- 
tential of some cancers (Reber et al., 1990; Giinthert et 
al., 1991; Matsumura nd Tarin, 1992; Heider et al., 1993; 
Hofmann et al., 1993; Koopman et al., 1993; Rudy et al., 
1993; Seiter et al., 1993; Tanabe t al., 1993). In rats, a re- 
gion of CD44 encoded by variant exon 6 (referred to here- 
after as CD44-6v) conferred metastatic potential to non- 
metastasizing pancreatic arcinoma cells (Giinthert et al., 
1991; Rudy et al., 1993). Moreover, a mAb recognizing rat 
1. Abbreviations used in this paper: APAAP, alkaline phosphatase anti- 
alkaline phosphatase; CD44s, standard CD44; CD44v, variant CD44; 
HPRT, hypoxanthine phosphoribosyltransferase; PE, phycoerythrin. 
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CD44-6v (Matzku et al., 1989) blocked invasion of these 
carcinoma ceils into the draining lymph nodes and the lung, 
possibly by interfering with the binding of CIM4-6v to a 
ligand in these tissues (Reber et al., 1990; Seiter et al., 
1993). An analysis of human breast and colon carcinoma 
using reverse transcribed PeR revealed a gross over-pro- 
duction of CD44-6v, or CIM4-8v-10v, in contrast to normal 
tissues in which only the standard form was detected (Mat- 
sumura nd Tarin, 1992; Heider et al., 1993; Koopman et al., 
1993; Tanabe t al., 1993). In humans and rats, CD44-6v 
is transiently expressed on B cells, T cells and macrophages 
after stimulation (Arch et al., 1992; Koopman et al., 1993). 
The ubiquitous expression of CD44, its complex structure 
and its involvement in tumor progression underscores a need 
to determine the expression, regulation and function of 
CD44 isoforms. This paper reports on the differential ex- 
pression and modulation of a number of CD44v isoforms, 
assessed using a panel of newly generated isoform-specific 
mAbs. 
Materials and Methods 
Cells and Tissues 
The characteristics and culture requirements of most of the cell lines used 
in this study have been described previously (Hofmann et al., 1991). Pri- 
mary fibroblasts derived from human neonatal foreskin were provided by 
Professor W. Miiller, Kinderspital, Basel. All other cell lines originated 
from the American Type Culture Collection (Rockville, MD). Normal hu- 
man tissues were obtained immediately postmortem, or from biopsies or 
resected tissues after surgery. Tissues for immunohistological staining were 
snap frozen in liquid nitrogen and stored at -70"C until use. 
Monoclonal A n tibodies 
A panel of mAbs was produced against the variant regions of human CD44 
by immunizing mice with a fusion protein corresponding to exons 3v to 10v 
of the variant region (Giinthert, 1993). Mice were immunized i.p. with 100 
#g of fusion protein, three times over a period of 6 wk. 4 d after the last 
immunization, the spleen was taken and cell fusion performed using the cell 
line SP2/O, as described (Harlow and Lane, 1988). The mAbs 11.24 and 
11.31 are IgG1 isotype, and mAbs 11.9 and 11.10 are IgGEa isotype. Other 
mAbs used in this study included anti-CIM4 standard mAbs 25-32 (Mackay 
et al., 1988), F10-44-2 (Flanagan et al., 1989) (Serotec, Oxford, UK) and 
Hermes-3 (Jalkanen et al., 1987) (kindly provided by Dr. Sirpa Jalkanen). 
A mAb termed 14-14 specific for c~6 integrin was produced in our labora- 
tory. The ICAM-1 specific mAb RR/I was a gift of Dr. T. Springer. Phyco- 
erythrin-labeled antibody to CD20 was purchased from Becton Dickinson 
(Mountain View, CA). 
Immunofluorescent Staining and Flow Cytometry 
For one color immunofluorescence staining, 106 cells were reacted with 50 
~,1 of hybridoma supernatant for 30 rain at room temperature (RT). The 
mAbs 11.10 and 11.9 were found to stain more effectively at RT. Cells were 
then washed once and resuspended in 50/zl of FITC goat anti-mouse Ig 
(Cappel Laboratories, Cochranville, PA). After 10 min at 4°C, the cells were 
washed twice and analyzed using a FACS ® (Becton Dickinson). Propidium 
iodide was used to identify and exclude dead ceils from analysis. For two- 
color immunofluorescence, cells were stained as described above, and were 
then stained with phycoerythrin (PE)-conjugated mAb by first blocking un- 
occupied sites on the FITC goat anti-mouse Ig using 20 ml of 10% normal 
mouse serum, and then adding an appropriate amount of PE-conjugated 
mAb. After 10 min at 4°C, the cells were washed twice and analyzed using 
the FACS °. Electronic gating was performed to analyze cells of interest. 
Monocytes and granulocytes were identified within human blood buffy coat 
cells by their forward angle and side scatter profile. T cells and B cells were 
identified with anti-CD3-PE and anti-CD20-PE, respectively. CD45RO 
and CD45RA T cells were identified using anti-CD45RA-PE together with 
biotinylated anti-CD3 and Cy-Chrome-labeled streptavidin (PharMingen, 
San Diego, CA). 
In vitro Stimulation of Cells with Cytokines 
or Mitogens 
In vitro stimulation of human T cells or T cell clones with phytohemaggluti- 
nin (PHA) or in the mixed leukocyte reaction (MLR) followed previously 
published procedures (l.anzavecchia, 1985). The effect of various cytokines 
on the expression of CD44 and other adhesion molecules was determined 
by incubating various cell lines in 25-ml tissue culture flasks. Cells were 
treated for 1, 3, or 6 d with recombinant cytokines at the following concen- 
trations: TNFc~ and TGFB at 10 ng/ml, IFN% GM-CSF, IL-4 at 250 U/ml, 
and IL-1 at 50 U/ml. TNFc~ and IFN3, were obtained from the central re- 
search department of Hoffmann La Roche, from Drs. Werner Lesslauer and 
Gianni Garotta. GM-CSF, IL-4, TGF-B and IL-1 were purchased from Brit- 
ish Biotechnology (Owen, UK). 
Fusion Proteins, Synthetic Peptides, and ELISA 
The CD44v region covering exons 3v to 10v was cloned from eDNA via 
PCR amplification. The two PCR primers (5' GTACGTCTTCAAATAC- 
CATCTCAGCAGCd2T, and 5' CTGATAAGGAACGATIC_xACATTAGAGT- 
TGG) correspond topositions 1to 30 and positions 1014 to 985, respectively, 
of the exons 3v to 10v, as described (Hofmann et al., 1991). To insert he 
PCR product directly into the glutathione transferase fusion vector pGEX- 
2T (Smith and Johnson, 1988), EcoRI sites were added at the 5' ends of the 
primers. The resulting plasmid pGEX-CD44(3v-10v) codes for a fusion 
protein of •85 kD. Subclones were constructed by using appropriate r - 
striction sites and inserted into the pGEX expression system: fragment 1
(position 2-320), fragment 2 (position 377-583), fragment 3 (position 638- 
1014), fragment 4 (position 1-244), fragment 5 (position 256--476), frag- 
ment 6 (position 483-830), fragment 7 (position 830-1014), fragment 8 (po- 
sition 320-483), fragment 9 (position 144-486), fragment 10 (position 486-- 
720), fragment 11 (position 699-916) (see Fig. 1 A). Fusion proteins were 
prepared after isopropyl-B-D-thiogalacto-pyranoside induction of the tac 
promoter as described (Smith and Johnson, 1988). Briefly, cells were resus- 
pended in PBS containing 1% Triton X-100, 0.5% Tween 20, 0.03% SDS 
(PBS-TTS) and sonicated. Ghitathione Sepharose beads (Pharmacia, Frei- 
burg, FRG) were added to the bacterial lysate. After washing the affinity 
matrix several times with PBS-TTS, elntion was performed with PBS con- 
taining 5 mM ghitathione. Aliquots of the preparations were run on 10% 
SDS polyacrylamide gels (Laemmli, 1970) and stained with Coomassie 
blue for control of purity. Synthetic peptides were constructed as16- or 20- 
mer overlapping sequences covering human exons 3v to 10v (Hofmann et 
al., 1991). All peptides were synthesized on a Rink amide Am resin (Nova- 
biochem USA, La Jolla, CA) using the ABIMED Ares 422 Multiple Peptide 
Synthesizer, utilizing Fmoc-chemistry. The amino acid sequences of the 
peptides were as follows: (1) OTSSNTISAG'WEPNEENEDE; (2) WEP- 
NEENEDERDRHLS; (3) NEDERDRHLSFSGSGIDDDE; (4) IDDDED- 
FISSTISTTP; (5) PRAFDHTKQNQDWTQWNPSH; (6) NPSHSNPEV- 
LLQI'TI'RMTDV; (7) RMTDVDRNGTTAYEGN; (8) GTTAYEGNWN-PE- 
AHPPLIHH; (9) EAHPPLIHHEHHEEEE; (10) HHEEEETPHSTSTIQ- 
ATPSS; (11) IQATPSSTTEETATQKEQWF; (12) EETATQKEQWFG- 
NRWHEGYR; (13) NRWHEGYRQTPREDSH; (14) TPREDSHSTTGT- 
AAASAHTS; (15) TAAASAHTSI-IPMQGRT; 06) TSHPMQGRTTPSPED- 
SSWTD; (17) EDSSWTDFFNPISHPM; (18) PTANPNTGLVEDLDRT; 
(19) SFSTSHEGLEEDKDHP; (20) LEGYTSHYPHTKESRT; (21) VTS- 
AKTGSFG'VTAVTV. 
ELISA was performed by coating fusion proteins from the pGEX sub- 
clones onto 96-well microtiter plates, at a concentration f 5-10 #g/ml, for 
at least 4 h at 4°C. After washing, the wells were then incubated with anti- 
CD44v antibodies for 2 h at room temperature, washed with PBS and in- 
cubated with HRP-coupled goat anti-mouse IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA). The substrate used for the color reaction 
was 2,2-'azino-di [3-ethylbenz-thiazoline-6-sulfonic acid],which was mea- 
sured at 405 nm in an ELISA reader. For a more defined localization of the 
epitope specificity of the CD44v-specific mAbs, fusion protein pGEX- 
CD44(3v-10v) was coated onto the wells, and 16-20-mer synthetic peptides 
at a concentration f 10 t~g/ml were used to block reactivity of the mAbs. 
Immunohistochemistry 
5-t~m frozen sections were prepared and immunostained using the alkaline 
phosphatase anti-alkaline phosphatase (APAAP) technique (Cordell et al., 
1984). Briefly, sections were air dried, fixed in acetone for 5 rain and were 
then incubated, successively, with hybridoma supernatant diluted 1:30 to 
1:100 for 30 rain, anti-mouse Ig, APAAP complex (Dakopatts, Denmark), 
and the substrate for the color reaction (Napthol AS-BI phosphate/New 
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Fuchsin; Sigma Chemical Co., Deisenhofen, FRG). mAbs of irrelevant 
specificities were used as a first step negative controls. The immunostaining 
results were evaluated semi-quantitatively and classified as follows: strong 
expression, +++;  moderate expression, ++; weak expression, +; and no 
detectable expression, - .  
Immunoprecipitation andSDS-PAGE 
Immunoprecipitation of radio-labeled molecules and SDS-PAGE followed 
standard procedures (Harlow and Lane, 1988). Briefly, HPKII cells were 
labeled with [35S]methionine (Amersham) by incubation for 4 h with 
1 mCi in a 75-ml tissue culture flask. The lysis buffer used to solubilize cells 
consisted of 2% NP-40 (Sigma Chemical Co.) in 20 mM Tris-HCl pH 8, 
1 mM MgCI2, 150 mM NaC1, and 0.1 mM PMSE Protein A- and Protein 
G-Sepharose (Pharmacia) were used for preclearing lysates and for isolating 
precipitated material. For immunoblotting, cells were incubated on ice in 
a buffer containing 10 mM Hepes, pH 7.9, 60 mM KC1, 1 mM EDTA, 
1 mM DTT, 1% Triton X-100, I mM PMSE and 10/~g/m! Aprotinin (Sigma 
Chemical Co.). The cell lysate was mixed vigorously and centrifuged at 
13,000 g for 10 rain. The supernatant was adjusted to gel sample buffer, 
boiled for 5 rain, and proteins were separated on 7.5-15% gradient poly- 
acrylamide SDS gels under reducing conditions (Laemmli, 1970). 
Semiquantitative Reverse Transcribed PCR 
The myelomonocytic cell lines THP-1 and U937 were treated with TNFa 
and IFN3, for 24 h as described above. Approximately 106 cells were taken 
for RNA preparation using the method of Chomczynski and Sacchi (1987) 
including modifications by Keller et al. (1993). eDNA synthesis was per- 
formed using random hexanucleotide primers (Promega, Heidelberg, FRG) 
and mouse mammary leukaemia virus reverse transcriptase (Promega). The 
relative xpression of hypoxanthine phosphoribosyltransferase (HPRT) was 
used for standardising the reaction. The following primers were used: 
CCAAAGATGGTCAAGGTCGC (5' sequence; positions 448--467) and CTG- 
CTGACAAAGATTCACTGG (3' sequence; positions 1292-1272), yielding 
a HPRT cDNA product of 0.84 kb. 
Based on densitometric s anning of the HPRT products, the amount of 
cDNA for the CD44 reactions was adjusted, according to the procedure 
from Keller et al. (1993). CD44 PCR was performed using the primers 
GCACAGACAGAATCCCTC~TACC, 5' sequence, positions 759-781 from 
Stamenkovic etal. (1989) and GGGGIV_d3AATGTGTCTTGGTCTC, 3' se- 
quence, positions 805-783 from Stamenkovic et al. (1989), which are lo- 
cated in the CD44s sequence directly flanking the variant exons. Depending 
on the composition and number of variant exons expressed, products of 
different lengths and quantity were produced. CD44s yields a product of 
67 bp, because the primers used have additional 10-bp extensions at their 
5' ends for easier cloning. 
The PCR reactions were done as follows: 96°C for 5 s, 50°C (HPRT) 
or 60°C (CD44) for 15 s, and 72°C for 60 s over 30 cycles, followed by 
72°C for 10 min in an Ams Biotechnology thermal cycler. Controls were 
treated identically, except for replacing the eDNA by water. 7-~1 aliquots 
of the 30-/~1 reactions were separated on 1.2% agarose gels, followed by 
alkaline blotting onto Hybond N + membranes (Amersham). Membranes 
were then hybridized under stringent conditions (65°C) with the following 
ot-32p dCTP labeled human CD44 probes: exons 5v + 6v, positions 
242-467, exon 6v, positions 361-467, exons 8v, 9v + 10v, positions 
623-980 (Hofmann et al., 1991) and exons 5s + 6s, positions 561-825 
(Stamenkovic et al., 1989). After a short exposure to Hyperfilm-MP 
(Amersham), the amount of radioactivity bound was scanned using a phos- 
phoimager. 
Results 
Production of mAbs Against Human CD44 
Variant Regions 
A scheme of the full length uman CD44 molecule, illustrat- 
ing the organization ofthe variant exons, is shown in Fig. 1 
A. A bacterially synthesized fusion protein was constructed 
in the pGEX expression system encoding exons 3v-10v. This 
protein was used to immunize Balb/c mice, from which a 
number of CD44v-specific mAbs were derived. The spec- 
ificity of the various mAbs for the different exon products 
was determined by ELISA, using smaller fusion proteins en- 
coded by the variant exons (Fig. 1 A). A more precise deter° 
mination of the epitope specificities was achieved by blocking 
the reactivity of the antibodies for the fusion protein CD44- 
(3v-10v) with 16-20-mer peptides corresponding to specific 
regions of the CD44v sequence (Fig. 1, A and B). A large 
number of variant-specific mAbs were generated, but only 
a proportion of these reacted with the fully processed CD44v 
regions, as revealed by flow cytometry of human cells (see 
below). This presumably relates to posttranslational modi- 
fications or folding of the CD44 molecule synthesized in eu- 
karyotes, which leads to a loss of specificity of some of the 
fusion protein-reactive mAbs. The specificity of those mAbs 
reactive with naturally expressed CD44v regions is mAb 
11.10: exon 4v, 11.9 and 11.31: exon 6v; and 11.24: exon 9v 
(Fig. 1 A). The sequences of the peptides that blocked the 
reactivities of these antibodies in the ELISA were, respec- 
tively, No. 5: PRAFDHTKQNQDWTQWNPSH (positions 
4%66); No. 12: EETATQKEQWFGNRWHEGYR (posi- 
tions 129-148) and No. 19: SFSTSHEGLEEDKDHP (posi- 
tions 247-262, from Hofmann et al., 1991). The epitopes for 
mAb 11.9 and 11.31 are located in the same region as for 
mAb 1.1 ASML, known to block metastasis formation i  the 
rat (Seiter et al., 1993). 
To confirm the reactivity of mAbs 11.10, 11.9, and 11.24 
with CD44 variants, immunoprecipitations were performed 
using lysates prepared from the HPKII keratinocyte c ll line, 
which expresses predominantly CD44v regions 3v-10v (Hof- 
mann et al., 1991). Immunoprecipitation of CD44 from an 
[35S]methionine lysate of HPKII using Hermes-3, 25.32, or 
F10-44-2 (anti-CD44s mAbs which recognize pitopes in 
the 5' standard region and precipitate all isoforms) showed 
that CD44 was expressed as multiple forms, migrating at 
130, 190, and 250-300 kD (Fig. 1 C). Precipitation ofCD44 
from ~25I-lactoperoxidase surface-labeled HPKII revealed 
the same bands (not shown). Hermes-3, 25.32 and F10-44-2 
showed slightly different precipitation patterns, presumably 
because of different affinities for the distinct sizes. The 
variant-specific mAbs 11.24 (9v-specific), 11.10 (4v-specific), 
and 11.9 (6v-specific) precipitated molecules of similar size 
to the CD44s-specific mAb but with varying intensities: 
11.24 precipitated the 130-, 190-, and 250-300-kD compo- 
nents, 11.10 predominantly he 130-kD component, and 11.9 
a 250-300-kD component (Fig. 1 C). 
Western blot analyses with mAb 11.24 and 11.10 using 
protein extracts from different cell lines confirmed the im- 
munoprecipitation data (not shown), mAb 11.31 and 11.9 did 
not react with denatured CD44 proteins. 
CD44 Variants are Expressed Differentially 
by Various Epithelia 
Previous studies using PCR, Northern blot analysis, and 
mAbs against CD44-6v have shown that some normal tissues 
express CD44v isoforms, although results have been con- 
tradictory (Brown et al., 1991; Dougherty et al., 1991; Giin- 
thert et al., 1991; Stamenkovic etal., 1991; Matsumura and 
Tarin, 1992; Heider et al., 1993; Salmi et al., 1993). An 
analysis of different tissues using the variant-specific mAbs 
and APAAP immunohistochemical st ining showed in fact 
that CD44v isoforms were expressed widely (Fig. 2 and Ta- 
ble I). There were three main findings. First, the most in- 
tense and extensive xpression of variant isoforms was by 
epithelium, and epithelium from most tissues expressed 
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Figure 1. (A) Schematic presentation f the standard and the variant CD44 regions. At amino acid 223 in human CD44, up to 381 additional 
amino acids may be present, due to alternative splicing of 9 or 10 variant exons. The region encoding exons 3v-10v was isolated by reverse 
transcribed PCR and inserted into pGEX-2T to produce aglutathione transferase fusion protein which was used as an immunogen to pro- 
duce mAbs. Subelones were generated and pGEX fusion proteins ynthesized (fragments numbered 1-11, shown at the bottom) to determine 
the specificity of anti-variant mAbs in an ELISA. The exact positions of fragments 1to 11 are indicated in Materials and Methods. The 
mAbs that were reactive with individual fragments i  the ELISA are indicated at the left hand side. (B) Synthetic peptides encoding specific 
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CD44-9v. Other cell types including stromal elements, con- 
nective tissue, blood vessels and muscle expressed only 
CD44s as previously described (Mackay et al., 1988; Flana- 
gan et al., 1989; Picker et al., 1989). Second, the variant 
exons were expressed differentially in the various epithelial 
tissues, in that most epithelia expressed CD44-9v whereas 
fewer epithelial tissues expressed 6v or 4v. CD44v were ex- 
pressed most intensively in stratified squamous epithelium, 
particularly in oesophagus, skin and tonsil (Table I and Fig. 
2, A and B). Third, within an epithelial layer (e.g., oesopha- 
gus), the different CD44v isoforms had a non-uniform ex- 
pression; exon 4v products were expressed toa lesser degree 
than exon 6v products, which in turn were expressed less 
than exon 9v containing isoforms (Table I and Fig. 2 A). The 
generative pithelial cells expressed the highest levels of 
CD44v. Thus the basal cells of stratified squamous epithe- 
lium such as oesophagus and skin expressed high levels of 
all of the CD44v exon products. Epithelium of the skin 
stained intensely for 9v and 6v but slightly less for 4v (Fig. 
2 B). The generative cells of intestinal epithelium, situated 
in the lower part of the crypts, expressed CD44-9v but not 
4v or 6v (Fig. 2 C). The base of glands of the stomach 
showed a similar pattern of expression (not shown). 
Staining of epithelial cell lines with anti-CD44v mAbs, 
using FACS ® analysis, showed that most epithelial cell lines 
expressed CD44-9v. In general, the expression of CD44v on 
cell lines detected by flow cytometry correlated with the 
expression of CD44v in tissues by immunohistochemistry. 
Thus, squamous epithelial cell lines (i.e., HPKII) expressed 
CD44-4v, -6v and -9v, whereas cell lines derived from glan- 
dular epithelium usually expressed only CD44-9v. One co- 
lon carcinoma line (HT29) expressed CD44-9v, while others 
were negative (COLO 320) (Hofmarm et al., 1991), possibly 
reflecting the differential expression of CD44-9v within in- 
testinal epithelium (see Table I). A neuroblastoma line (SH- 
EP) and an astrocytoma line (1321 NI) expressed low levels 
of CD44-9v, and were 6v- and 4v-negative. Other cell types 
such as primary fibroblasts, a melanoma cell line (MeWo) 
and cultured endothelial cells were positive only for CD44s 
(not shown). 
Immunocytochemical staining of growing HPKII ker- 
atinocytes revealed a distinct distribution of CD44v: the 
spreading edge of the culture expressed high levels of the 
variant isoforms, particularly in the filopodia (not shown). 
Leukocytes Express Predominantly CD44-9v 
and not 6v 
Fig. 3 shows the expression of CD44v isoforms on various 
leukocyte types, as revealed by FACS ® analysis with mAbs 
11.24, 11.9, and 11.10. CD44-9v isoforms were weakly ex- 
pressed on T and B cells, monocytes and granulocytes, but 
not on thymocytes. Only monocytes xpressed CD44-6v and 
-4v isoforms and at low levels. However, after activation with 
PHA or in the MLR, CD44-9v and to a lesser extent CD44- 
6v were upregulated on T cell lines (Fig. 3). Only a minor 
proportion of the CD44 molecules on activated T cells and 
other leukocytes contained variant sequences, ince intense 
staining was observed with antibodies to CD44s, but much 
lesser staining with mAbs 11.24 or 11.9 (Fig. 3). Upregula- 
tion of CD44-9v and CD44-6v on stimulated T cells oc- 
curred within 24 h and was transient, since expression of 
these determinants decreased to pre-stimulation levels by 
day 6; other activation markers uch as CD26 and IL-2R were 
expressed for much longer periods. In addition, CD45RO + 
T cells which are memory/previously activated cells, ex- 
pressed slightly higher levels of CD44-9v than did CD45RA + 
(naive) T cells (not shown). In contrast to peripheral T cells, 
thymocytes did not express CD44-9v or CD44-6v at all. It 
has been suggested that CD44 is an adhesion molecule for 
pro T cell homing to the thymus (Hyman et al., 1986), 
but gating on early stage CD4-CD8- thymocytes revealed 
that they were CD44-9v- and 6v- although mostly CD44 hi 
(not shown). 
Immunohistochemical analysis of thymus tissue sections 
confirmed that CD44v molecules were not expressed on 
thymocytes, although epithelial cells within Hassall's cor- 
puscles were stained by all of the variant-specific mAbs (Ta- 
ble I). Staining of various lymphoid tissues revealed an ab- 
sence of staining of CD44v on lymphocytes, presumably 
because the APAAP technique is not as sensitive as FACS ® 
analysis. However plasma cells in the bone marrow were 
clearly stained by 11.24, and pulmonary macrophages were 
stained by mAbs 11.24 and 11.9 (not shown). 
TNF~ and IFN~/ modulate CD44 Isoforms on 
Monocytic Cell Lines 
CD44 expression on various cell lines was examined after 
their incubation with different cytokines. TNFa has been 
reported to upregulate CD44 on human endothelial cells 
(Mackay et al., 1993), and using anti-CD44s mAbs we 
found a similar upregulation of CD44 on the myelomono- 
cytic cell lines THP-1 (Fig. 4 A) and U937. On myelomono- 
cytic cell lines, IFN~/ also modulated CD44 expression, 
whereas IL-1, IL-4, GM-CSF, or TGF/~ had little effect (Fig. 
4A). More significant was the fact that CD44v isoforms were 
differentially upregulated on myelomonocytic cell lines. Both 
TNFa and IFN3, modulated CD44-9v and -6v expression, 
and their upregulation was much more apparent than that 
of CD44s. Moreover, TNFot preferentially upregulated 
CD44-9v, whereas IFN7 preferentially upregulated CD44-6v 
(Fig. 4 A). However the upregulation of CD44v on THP-1 
by TNFa or IFN'y was less than that of ICAM-1, an adhesion 
molecule well characterized for its upregulation i  response 
to inflammatory cytokines (Springer, 1990). The effect of 
regions of CD44 (3v-lOv) were used to localize the exact epitope positions for mAbs 11.10, 11.31, 11.9, and 11.24. 21 different peptides 
were used to block the reactivity in the ELISA of the various mAbs against fusion protein CD44 (3v-10v). The regions of CD44 to which 
the 21 peptides correspond are indicated inFig. 1A and their sequences are givenin Materials and Methods. The specificities of the different 
mAbs are also indicated in A. The epitope for mAb 25.32 (anti-standard) has been localized to exon 5s, using a fusion protein encoding 
this region (not indicated). (C) Immunoprecipitation of 3sS-labeled proteins from an HPKII keratinocyte c ll lysate. The lysate was pre- 
pared as described inMaterials and Methods and aliquots were incubated with the indicated mAbs. Immunoprecipitated material was sepa- 
rated on 7.5-15% SDS polyacylamide gradient gels. 
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Figure 2. Expression of CIM4v in human 
epithelial tissues. Oesophagus (A), skin (B), 
or small intestine (C) were stained with 
mAbs to CIM4s (25.32), CD44-9v (11.24), 
CD44-6v (11.9), and CIM4--4v (11.10) using 
the APAAP technique. A more extensive 
description of the reactivity of these mAbs is 
given in Table I. Bars, 65/zm. 
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Table I. Differential Expression of CD44 lsoforms within Epithelia from Various Human Tissues 
Epithelial 
tissue within mAb 25.32 (CD44s) mAb 11.24 (CD44-9v) mAb 11,9 (CD44-6v) mAb 11.10 (CD44-4v) 
Skin 
Epidermis  + + + + + + 
Hair  fol l ic les + + + + + + 
Sweat glands + + + + + + 
Small  intestine + + + + 
(base of  crypts) 
Large intestine + + + + + 
(base of crypts) 
Stomach + + + + + 
(base of glands) 
Pancreas 
Acini  
Ducts 
Kidney 
Tubular  region 
L iver  
Bile ducts 
+++ +++ 
+ + 
(some) (some) 
++ +++ 
(some) 
+++ +++ 
+++ +++ 
+++ 
Lung 
Bronchial  epith. + + + + + + + 
Oesophagus + + + + + + + + + 
Thyroid gland + + + + + - 
Sal ivary g land + + + + + + - 
Mammary  gland + + + + + + + 
(basal layer) (basal layer) 
Adrenal  gland - - - 
Ovary - - - 
Endometr ium + + + + + - 
(basal layer) 
Ep id idymis  + + + + + + - 
(basal layer) 
Prostate gland + + + + + + + 
Ur inary tract + + + + + + - 
Tonsi l  + + + + + + + + 
Thymus + + + + - 
Hassal l 's Corpuscles + + + + 
+++ 
(basal layer) 
++ 
+ 
the cytokines on THP-1 was also examined after 1, 3, and 6 d 
of exposure, showing a slight decrease at day 6 as compared 
to the values after 24 h (Fig. 4 A). No modulation of CD44-4v 
was observed (not shown). 
The modulating effect of TNFot and IFN3, on THP-1 and 
U937 was confirmed by reverse transcribed PCR (Fig. 4 B). 
This allowed a better assessment of the upregulation of 
CD44v in comparison to CD44s. As shown in Fig. 4 B, 
CD44s was not induced in THP-1 or U937 by TNFot or 
IFNy, as tested using a probe for CD44s. However CD44-9v 
and 6v were both markedly upregulated by TNFot and IFN% 
A semiquantitative evaluation of the PCR products revealed 
an increase for the epithelial variants, most likely comprising 
exons 8v, 9v + 10v (larger band) and exons 9v + 10v or 8v 
+ 10v (smaller band) by 2-3 fold as compared to the non- 
treated cells. Modulation of these xons by TNFot and IFN3, 
was less prominent in U937 cells than in THP-1 cells (Fig. 
4 B). The probe comprising exons 5v + 6v detected pre- 
dominantly a small band of 200 bp, which was also upregu- 
lated by TNFot and IFNy 2-3-fold in both cell lines. This 
product represents only exon 6v as revealed by sequencing. 
In addition to this variant, THP-1 cells also produced larger 
bands, comprising variant sequences that included exons 7v 
and/or 6v. These larger bands were also upregulated 2-3- 
fold especially upon IFNy stimulation. 
Modulation of CD44 on Epithelial Cell Lines by INFy 
The effect of cytokines on CD44 expression was also exam- 
ined on epithelial cells. IFN'y was the only cytokine that had 
a marked effect on CD44 or ICAM-1 expression on epithelial 
cell lines. Although epithelial cell lines varied in their re- 
sponse to IFNy, a common effect was an upregulation of 
CD44-6v, and a downregulation or maintenance of other iso- 
forms and CD44s expression. This is shown for the large 
lung cell carcinoma LCLC97, the colon carcinoma HT29, 
and the keratinocyte line HPKII (Fig. 5). By FACS ® analysis, 
CD44s expression on the cell lines was usually downregu- 
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Figure 3. FACS ® analysis of human leukocytes stained with mAbs 
specific for CD44-4v (11.10), CD44-6v (11.9), CD44-9v (11.24), 
and CD44s (25.32). T cells, B ceils, a PHA-stimulated T cell clone, 
thymocytes, monocytes, and granulocytes were stained with the 
various mAbs, and in each plot staining with the individual anti- 
body is indicated. T cells and B cells were gated electronically after 
two-color immunofluorescence staining, using PE-labeled mAbs to 
CD3 and CD20. Monocytes and granulocytes were identified ac- 
cording to their forward angle and side scatter. 
lated ,,o2-5-fold by the treatment, as was to a lesser extent 
CD44-9v, whereas CD44-6v was upregulated ~o3-5-fold 
(Fig. 5 A). ICAM-1 was included as a control, and was con- 
sistently upregulated 5-10-fold by IFN% whereas the ex- 
pression of a6 and ~2 integrins were unaffected (not shown). 
A similar effect for IFN'y treatment on CD44 expression was 
seen with other epithelial cell lines, including HaCaT (ker- 
atinocyte line), and WI-38 (lung epithelial line, not shown). 
The characteristic pattern of CIM4 modulation observed by 
FACS ® staining was also confirmed by RT PCR. As shown 
in Fig. 5 B, LCLC97 cells upregulated an exon 6v containing 
RNA, but downregulated CD44s. This effect was most prom- 
inent after 24 h of IFN-/treatment, but was not apparent 
upon incubation with TNFo~ apart from a slight downregula- 
tion of CIM4s. Expression of the epithelial variant (exons 8v, 
9v, and 10v containing isoforms) was also slightly downreg- 
ulated by the cytokine treatment, paralleling the FACS ® 
data. In contrast to LCLC97 cells, the cholangiocarcinoma 
line RPMI7451 which was also analyzed by RT PCR (and 
FACS ® not shown) neither up- nor downregulated CD44 or 
CD44v upon TNFot and IFN~( treatment (Fig. 5 B), illustrat- 
ing that CD44 was not modulated on all epithelial lines 
by Irrq-/. 
Discussion 
CD44 is a complex molecule that has been implicated in 
many functions. In this report, we studied the expression and 
modulation ofthe variant isoforms of human CIM4 by gener- 
ating mAbs against a fusion protein encoding the variant 
exons 3v-10v. This study shows that CD44 variant isoforms 
are expressed widely throughout the body, that CIM4v exon 
products are expressed on epithelium in a differential man- 
ner, and that expression of CIM4 and CIM4 variants can be 
modulated by certain cytokines. 
The extensive expression of CD44v isoforms within many 
normal epithelia most likely serves an adhesive function 
relating to the interaction and migration of the resident ceils. 
There is an ongoing process of epithelial cell regeneration, 
differentiation, and migration, especially during embryogen- 
esis and wound healing, which involves changes in surface 
phenotype and adhesive properties of cells (Weigel et al., 
1986; Woodley et al., 1986; Adams and Watt, 1990). Within 
epithelial tissues, CD44v isoforms were expressed most in- 
tensely by the generative cells, such as the basal ceils of 
squamous epithelia, or the cells of glandular epithelium. 
These epithelial cells have a rapid rate of proliferation (Chang 
and Leblond, 1974; Watt, 1984; Gordon, 1989), suggesting 
that CD44v expression may somehow correlate with pro- 
liferation. A previous tudy also noted the close relation- 
ship between expression of hyaluronate r ceptors and prolif- 
eration by epithelial cells (Alho and Underhill, 1989; Brown 
et al., 1991). In addition, expression of proteoglycans is 
known to relate to cellular proliferation (Hardingham and 
Fosang, 1992; Wight et al., 1992). The generative cells in 
the crypts of the small intestine give rise to progeny that mi- 
grate out of the crypts and move to the top of the villus 
(Gordon, 1989). Similarly, the generative cells of the basal 
layer of squamous epithelium, such as in the skin and in the 
oesophagus, produce cells that differentiate and migrate up- 
wards (Watt, 1984). In this study we did not use mAbs to 
exon products other than CIM4-4v, 6v and 9v. However 
since certain exons are expressed together in domains (Hof- 
mann et al., 1991; Stamenkovic et al., 1991; Gtinthert, 
1993), we expect hat 6v will show a similar pattern of ex- 
pression to that of 7v (the "metastatic form"), and 9v will 
show similar patterns of expression to that of Sv and 10v (the 
"epithelial form"). 
Many studies have found an association between CD44v 
expression and malignant transformation r cancer metasta- 
sis (Reber et al., 1990; Giinthert et al., 1991; Matsumura 
and Tarin, 1992; Heider et al., 1993; Hofrnann et al., 1993; 
Koopman et al., 1993; Rudy et al., 1993; Salmiet al., 1993; 
Seiter et al., 1993; Tanabe t al., 1993). In certain human 
cancers, cells appeared to express an abnormal profile of 
CD44v molecules, for instance, 6v expression on colon car- 
cinomas (Heider et al., 1993), breast cancers (Matsumura 
and Tarin, 1992), or lymphomas (Koopman et al., 1993). 
Two possibilities might account for the expression of CD44v 
isoforms on metastasizing cells. First, expression of CD44v 
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Figure 4. (A) Upregulation ofCIM4 variant isoforms on the myelomonocytic cell line THP-1 by TNFa and IFN3,. Various cytokines were 
added to cultures of THP-1 cells for 24 h and then stained for CD44s (mAb 25.32), CD44-9v (m.Ab 11.24), CD44-6v (mAb 11.9) and 
ICAM-1 (mAb RR/1) and analyzed on the FACS*. (B). RT-PCR on TNFc~ and IFN3, stimulated myelomonocytic cell lines. THP-1 and 
U937 cells were treated with TNFct and 1FN3, for 24 h. RNA and cDNA were prepared as described in Materials and Methods. Quantitation 
of eDNA was performed by standardizing for equal amounts of HPRT cDNA (lower panel). CD44 PCR products were separated on agarose 
gels, blotted onto Hybond N + membranes and hybridized to the respective CD44 probes. Primers used and the positions ofthe pr bes 
are indicated in Materials and Methods. 
isoforms in abnormal amounts and/or compositions may ac- 
company malignant transformation. A second possibility is 
that the generative cells of epithelia which express the 
highest levels of CD44v isoforms are the cells that most often 
undergo malignant transformation. The uncontrolled growth 
of these cells coupled with the expression of CD44 isoforms 
and possibly other adhesion molecules and proteases might 
render them more invasive and metastatic. Hence the altera- 
tion in adhesive properties that CD44v isoforms confer on 
cancer cells would relate to the normal developmental pro- 
cesses that occur within epithelia and other tissues by prolif- 
erating and differentiating cells. Interestingly, other molecules 
involved in adhesion, proliferation and tissue regeneration 
have also been implicated in the metastatic spread of cancer 
cells (for review see Birchmeier et al., 1991; Van Roy and 
Marcel, 1992). CD44v isoforms are certainly not expressed 
on all metastasizing cancer cells, since all cases of malignant 
melanomas studied by us (our own unpublished observations) 
express only CD44s. CD44-6v shows a much more restricted 
expression i nonmalignant tissues compared with CD44-9v, 
however it is upregulated in some malignant tissues which 
normally express only low levels of CIM4-6v (Matsumura 
and Tarin, 1992; Heider et al., 1993). Recently, adownregu- 
lation of CD44-6v was shown to accompany malignant trans- 
formation of some squamous epithelia (Salmi et al., 1993). 
We found that most leukocyte cell types express very low 
levels of CD44v. Exon products of4v and 6v were virtually 
absent from lymphocytes, and likewise Koopman et al. 
(1993) and Salmi et al. (1993) found very little expression 
of CIM4-6v on leukocytes. In our study, CD44-9v was found 
to be the exon expressed most abundantly, although we esti- 
mate that CD44-9v still comprises not more than 5 % of total 
CD44, since staining with anti-CD44-9v was generally two 
logs lower than with anti-CD44s. On T cells, expression of 
CD44-9v and CD44-6v increased after stimulation, and this 
induction was rapid and transient. A study in rats showed 
that CD44-6v but not other CD44v exons were induced on 
T cells after stimulation (Arch et al., 1992). In our study, 
CD44-9v was more readily induced than CIM4-6v, and it 
was only the most acutely activated T cells that expressed 
CD44-6v. The expression of CIM4v on activated T cells 
might endow them with properties similar to those of metas- 
tasizing cancer cells. Some metastasizing cancer cells show 
remarkable tissue-selective migration patterns (Nicolson, 
1991), similar to the tissue selective migration patterns of ac- 
tivated T cells (Mackay, 1993). 
CIM4 is another adhesion molecule that is modulated by 
TNFc~ and IFN3,. On myelomonocytic cell lines, CD44 up- 
regulation was more modest compared with ICAM-1, an 
adhesion molecule well characterized for its upregulation i
response to inflammatory cytokines (Springer, 1990). A re- 
cent study using human endothelial cells also showed that 
CD44 was upregulated by TNFot (Mackay et al., 1993) and, 
in addition, TNFot has been reported to upregulate a mole- 
cule structurally related to CD44 on fibroblasts (Lee et al., 
1992). On myelomonocytic cell lines such as U937 and 
THP-1, TNFot as well as IFN3, induced CD44-9v and -6v, 
and on some epithelial cell lines IFN-/upregulated CD44- 
6v. In other studies using RNA expression analyses, we 
found that TNFct induced several CD44v isoforms in murine 
stromal cell lines (Gutierrez-Ramos, J. C., U. Gfinthert, and 
C. Mackay, manuscript in preparation). TNF~t also upregu- 
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Figure 5. (A) Modulation of CD44 variant isoforms on epithelial 
cells by IFN% IFN3, was added to cultures of LCLC97 cells (top), 
HT29 cells (middle), and HPKII cells (bottom) for 48 h and cells 
were then stained for CD44s (mAb Hermes-3), CD44-9v (mAb 
11.24), and CD44-6v (mAb 11.9) and analyzed on the FACS °. The 
profile for IFN3, treated cells is indicated in each plot. (B) RT-PCR 
on IFN3, and TNFcx stimulated epithelial cells. LCLC97 and 
RPMI7451 cells were treated with TNFc~ or IFN3, for 24 h. RNA 
and cDNA were prepared as described in Materials and Methods. 
Quantitation of eDNA was performed by standardizing for equal 
amounts of HPRT cDNA. The upper three panels how CD44 PCR 
products, blotted onto Hybond N + membranes and hybridized to 
the indicated probes. The two lower panels are ethidium bromide 
stained agarose gels, containing either the CD44 specific PCR 
products (fourth panel) or the HPRT equilibration products (bottom 
panel). 
lated CD44-9v on cultured human dendritic cells, in a simi- 
lar manner to that described here for myelomonocytic cell 
lines (Sallusto, F., and A. Lanzavecchia, manuscript submit- 
ted for publication). The basis for CIM4v uprcgulation on 
some c¢11 lines and not others is unknown. The modulation 
of CD44 expression by TNFa or IFN3, might also relate to 
epithelial migration and cancer metastasis. TNF,  has cyto- 
toxic effects on some tumor cell types (Vassalli, 1992), but 
in other cases it promotes cancer growth and metastasis 
(Malik, 1992; Orosz et al., 1993). TNFot also stimulates ep- 
ithelial cell motility in vitro (Rosen et al., 1991), which has 
led to speculation that this cytokine may play a role in wound 
healing, or the invasiveness of some carcinomas. Moreover, 
IFN'y not only modulates the interactions of leukocytcs with 
endothelium, but also plays an essential role in regulating 
neutrophil/epithelial dhesions in transmigration due to its 
effects on epithelial cells (Kvale et al., 1992; Colgan et al., 
1993). 
In this report we have compared the expression and modu- 
lation of three important regions of CD44, the metastatic 
form (containing exon 6v), the epithelial form (comaining 
exon 9v), and a rarely expressed region containing exon 4v. 
Antibodies against these different CD44v isoforms should 
prove invaluable for further analysis of CD44v expression, 
regulation, and function. 
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